STOCK TITAN

Vaccitech plc - vacc STOCK NEWS

Welcome to our dedicated news page for Vaccitech plc (Ticker: vacc), a resource for investors and traders seeking the latest updates and insights on Vaccitech plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaccitech plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaccitech plc's position in the market.

Rhea-AI Summary
Barinthus Biotherapeutics plc (NASDAQ: BRNS) will present data from its Phase 2 Hepatitis B trials of VTP-300 at The Liver Meeting® 2023. The company has changed its name from Vaccitech plc to Barinthus Biotherapeutics plc to represent its expanded focus. The new name is inspired by the mythological navigator Barinthus, who guided King Arthur to a place of healing. The company's new website is www.barinthusbio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.36%
Tags
none
-
Rhea-AI Summary
Vaccitech to host KOL Webinar discussing treatment landscape for chronic Hepatitis B and potential cure paths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
Rhea-AI Summary
Vaccitech plc will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023. The trial showed meaningful reductions of HBsAg in participants who received VTP-300 alone or in combination with a low-dose PD-1 inhibitor. Two patients achieved a non-detectable HBsAg level that persisted for eight months after the last dose. VTP-300 led to a decline in HBsAg in adults with chronic Hepatitis B, and VTP-300-elicited T cells showed cross-reactivity to HBV core antigen from genotypes A to E in vitro.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
Vaccitech plc

Nasdaq:VACC

VACC Rankings

VACC Stock Data

192.73M
28.30M
3.46%
49.84%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Harwell

About VACC

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit